Regulus Therapeutics Inc. or Regulus (NASDAQ: RGLS) is a biopharmaceutical company focused on the development of microRNA-based drugs targeting fibrosis, metabolism and cardiovascular diseases, cancer, HCV and immune-related diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals.
Regulus Therapeutics Inc (RGLS) Stock Drops on RG-101 Phase 2 Interim Data Regulus Therapeutics Inc. (NASDAQ:RGLS) shares plummeted over 10% today, after the company announced interim data from Phase 2 studies for RG-101, which treats Hepatitis C virus infection (HCV), at the International Liver Congress 2016 (ILC 2016), held in Barcelona, Spain. RGLS stock fell as low as 17.21% during the early trading hours. Read full article here: http://www.bidnessetc.com/67287-regulus-therapeutics-rgls-stock-drops-rg101-phase-2-interim-data/
